FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1841-1854 November 1, 2007 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Leukotrienes ("leuko," from white blood cells; and "trienes," three conjugated double bonds) comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metabolism. The cysteinyl leukotrienes C₄, D₄, and E₄ account for the biologic activity that was previously termed "slow-reacting substance of anaphylaxis," and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT₁) in asthma validates the importance of cysteinyl leukotrienes and CysLT₁ in this disease.¹ This article reviews both established understanding and recent advances in our knowledge about leukotrienes.

Synthesis of Leukotrienes

The synthesis of leukotrienes from substrate arachidonic acid is initiated by 5-lipoxygenase in . . . [Full Text of this Article]

Leukotriene Receptors

Blockade of Leukotriene Synthesis and Leukotriene Receptors

Leukotrienes in Disease

Asthma

            Antileukotriene Drugs as Controller Agents

            Effects of Antileukotriene Agents on Airway Remodeling

            Responsiveness to Antileukotriene Agents

            Therapeutic Trials of Antileukotriene Agents

Cardiovascular Disease

Cancer

Leukotrienes in Antimicrobial Defense

Conclusions

Source Information

From the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor (M.P.-G.); and the Center for Allergy and Inflammation, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle (W.R.H.).

Address reprint requests to Dr. Peters-Golden at the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, 6301 MSRB III, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-5642, or at petersm@umich.edu.

Related Letters:

Leukotrienes
Taccone-Gallucci M., Manca-di-Villahermosa S., Maccarrone M., Peters-Golden M., Henderson W. R. Jr.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:746, Feb 14, 2008. Correspondence

This article has been cited by other articles:

• Freiberg, J. J., Tybjaerg-Hansen, A., Sillesen, H., Jensen, G. B., Nordestgaard, B. G. (2008). Promotor Polymorphisms in Leukotriene C4 Synthase and Risk of Ischemic Cerebrovascular Disease. Arterioscler. Thromb. Vasc. Bio. 28: 990-996 [Abstract] [Full Text]  
• Backlund, M. G., Amann, J. M., Johnson, D. H. (2008). Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids. JCO 26: 825-827 [Full Text]  
• Taccone-Gallucci, M., Manca-di-Villahermosa, S., Maccarrone, M., Peters-Golden, M., Henderson, W. R. Jr. (2008). Leukotrienes. NEJM 358: 746-746 [Full Text]